Search results
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
FOX Business· 5 days agoThe State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoEarlier in the year, one analyst called results from the cancer vaccine study "transformational."...
Novavax Seeks FDA Nod for Updated COVID-19 Vaccine - Novavax (NASDAQ:NVAX), Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoNovavax's filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 1 day ago"Simply put, Novavax's Covid vaccine results have shown better tolerability cross-trial than mRNA ...
Moderna stock is lone omen of bird flu pandemic
Reuters· 5 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Kansas sues Pfizer over ‘misleading statements’ about COVID vaccine
The Hill via AOL· 5 days agoThe state of Kansas filed a lawsuit Monday against pharmaceutical company Pfizer, alleging the...
Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine...
LA Times via Yahoo News· 4 days agoBlaming the COVID vaccines for a tide of undocumented injuries and deaths is a popular theme in the...
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading...
Benzinga· 5 days agoAlso Read: European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech.
Gateway - The Root
The Root· 5 days agoThe Biden administration is expected to announce this week that Americans who got the Pfizer-BioNTech or Moderna vaccines will need the third shot to protect ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoThe company also unveiled promising results in...Pfizer is competing against GSK's Arexvy, which hit...